Schaeffer's Top Stock Picks for '25

Analyst Upgrades: Amazon.com, Inc., MBIA Inc., and Pfizer Inc.

Analysts upwardly revised their ratings on Amazon.com, Inc. (AMZN), MBIA Inc. (MBI), and Pfizer Inc. (PFE)

Nov 3, 2015 at 9:07 AM
facebook X logo linkedin


Analysts are weighing in on Internet retailer Amazon.com, Inc. (NASDAQ:AMZN), insurance issue MBIA Inc. (NYSE:MBI), and pharmaceutical blue chip Pfizer Inc. (NYSE:PFE). Here's a quick roundup of today's bullish brokerage notes on AMZN, MBI, and PFE.

  • As of last night's close at $628.35, AMZN shares have more than doubled year-to-date, boosted by a recent earnings beat. Despite receiving a price-target lift to $800 from $725 at Deutsche Bank overnight, though, the stock is pointed 0.3% lower pre-market. In recent months, option traders have been gambling on losses for Amazon.com, Inc., per data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Specifically, the equity's 50-day put/call volume ratio of 1.07 ranks in the bearish 92nd percentile of its annual range. In other news, AMZN will be opening its first physical bookstore today in Seattle, called Amazon Books, and announced an expanded family-leave policy (subscription required) to attract and retain talent.
  • MKM Partners boosted its assessment of MBI to "buy" from "neutral," ahead of the company's third-quarter earnings report tomorrow night. The bullish note has the shares up 2.7% ahead of the bell, as they try to claw their way back from a nearly 19% year-to-date deficit, as of Monday's close at $7.74. Option players have been rolling the dice on post-earnings upside for MBIA Inc., buying to open more than 18 calls for every put during the past two weeks. The corresponding ISE/CBOE/PHLX call/put volume ratio of 18.13 registers a mere 6 percentage points from a 12-month peak.
  • Amid reports that GlaxoSmithKline plc (ADR) (NYSE:GSK) rebuffed a PFE buyout attempt prior to the latter's talks with Allergan PLC (NYSE:AGN), shares of the blue chip saw their price target raised to $41 from $40 at Credit Suisse. As such, Pfizer Inc. is headed slightly higher in electronic trading, hoping to build on its 12.6% year-to-date advance, as of yesterday's close at $35.06. The options crowd certainly is expecting more upside from the drugmaker. At the ISE, CBOE, and PHLX, PFE has racked up a 10-day call/put volume ratio of 5.36 -- which ranks in the 84th percentile of its annual range. In other words, traders have been buying to open calls over puts at an accelerated clip of late.
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?